Gary Glick is chief executive of Scorpion Therapeutics. Courtesy of Scorpion Therapeutics. Scorpion Therapeutics is the latest biotech to debut in Boston, with $108 million in venture capital and a roster of local industry veterans. The startup is focused on targeted oncology, or “precision medicine” for cancer, and will be headed by Gary Glick, who comes most recently from Boston-based IFM Therapeutics. There, he brought three immunotherapy drugs to clinical trials in three years, closing big pharmaceutical deals for their rights with Bristol Myers Squibb and Novartis.